Get the Stockscreener App
1.32
3.94%
0.05
Pre-market:
1.32
Fate Therapeutics Inc Stock (FATE) Forecast
The Fate Therapeutics Inc (FATE) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $10.55, representing a +699.09% increase from the current price of $1.32. The highest analyst price target is $14.41, and the lowest is $6.6812.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month FATE Price Target
Average 26.96
(+1,943% Upside)
Is Fate Therapeutics Inc (FATE) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 34.47 | Neutral |
| STOCH(9,6) | 22.00 | Neutral |
| STOCHRSI(14) | 32.81 | Neutral |
| MACD(12,26) | -0.2304 | Sell |
| ADX(14) | 18.34 | Neutral |
| William %R | -70.53 | Neutral |
| CCI(14) | -73.35 | Neutral |
Buy: 0
Sell: 1
Neutral: 6
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
1.446
Sell
|
1.4103
Sell
|
| MA20 |
1.5605
Sell
|
1.5814
Sell
|
| MA50 |
2.0466
Sell
|
2.0068
Sell
|
| MA100 |
2.6725
Sell
|
2.5296
Sell
|
| MA200 |
3.4161
Sell
|
3.0642
Sell
|
Buy: 0
Sell: 10
Neutral: 0
Summary: Sell
According to our latest analysis, FATE could be considered a Strong Sell, with 17 technical analysis indicators signaling 0 Buy signals, 11 signaling Sell signals and 6 Neutral signals. This might not be a good time to consider opening new positions on FATE, as trading bearish markets can be challenging and may result in losses.
- RSI (Relative Strength Index): The RSI(14) value of 34.47 indicates that FATE is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 22 indicates that FATE is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 32.81 indicates that FATE is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- ADX (Average Directional Index): The ADX value of The ADX value of 18.34 indicates that there is no clear directional movement, and the market may be ranging or moving sideways.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -73.35 indicates that FATE is still oversold but not to an extreme extent.
Long-term FATE price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Fate Therapeutics Inc financial reports and earnings history, Fate Therapeutics Inc (FATE) stock could reach $7.9123 by 2030, $10.22 by 2040 and $2.6927 by 2050. See the projected annual prices until 2050 of the Fate Therapeutics Inc stock below:
- Fate Therapeutics Inc (FATE) is expected to reach an average price of $5.8264 in 2035, with a high prediction of $6.6225 and a low estimate of $5.8665. This indicates an $341.39% rise from the last recorded price of $1.32.
- Fate Therapeutics Inc (FATE) stock is projected to chart a bullish course in 2040, with an average price target of $9.7304, representing an $637.15% surge from its current level. The forecast ranges from a conservative $9.949 to a sky-high $10.22.
- Our analysts predict Fate Therapeutics Inc (FATE) to jump 214.67% by 2045, soaring from $1.5778 to an average price of $4.1536, potentially reaching $3.3822. While $1.5778 is the low estimate, the potential upside is significant.
- Fate Therapeutics Inc (FATE) stock is expected to climb by 2050, reaching an average of $0.025, a $-98.10% jump from its current level. However, a wide range of estimates exists, with high and low targets of $2.6927 and $4.5727, respectively, highlighting the market's uncertainty.
Fate Therapeutics Inc Stock (FATE) Year by Year Forecast
Fate Therapeutics Inc Stock (FATE) Price Forecast for 2025
Fate Therapeutics Inc Stock (FATE) is expected to reach an average price of $22.93 in 2025, with a high prediction of $40.72 and a low estimate of $5.1319. This indicates an +1,637% rise from the last recorded price of $1.32.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| February, 2025 | $13.50 | $6.6812 | $14.41 | +923.09% |
| March, 2025 | $16.20 | $13.43 | $20.55 | +1,127% |
| April, 2025 | $10.59 | $5.1319 | $20.72 | +701.93% |
| May, 2025 | $19.02 | $8.38 | $20.62 | +1,341% |
| June, 2025 | $17.21 | $14.36 | $20.81 | +1,204% |
| July, 2025 | $20.61 | $16.54 | $26.07 | +1,462% |
| August, 2025 | $24.33 | $19.72 | $27.59 | +1,743% |
| September, 2025 | $23.04 | $19.35 | $25.21 | +1,645% |
| October, 2025 | $20.49 | $18.75 | $26.70 | +1,452% |
| November, 2025 | $29.49 | $18.81 | $30.88 | +2,134% |
| December, 2025 | $34.09 | $27.58 | $40.72 | +2,483% |
Fate Therapeutics Inc Stock (FATE) Price Forecast for 2026
The predicted value for Fate Therapeutics Inc (FATE) in 2026 is set at an average of $71.82. Estimates vary from a peak of $111.27 to a trough of $32.37, indicating an +5,341% surge from the present price of $1.32.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $47.75 | $32.37 | $48.79 | +3,518% |
| February, 2026 | $83.47 | $46.38 | $93.63 | +6,223% |
| March, 2026 | $103.70 | $74.24 | $111.27 | +7,756% |
| April, 2026 | $100.46 | $70.69 | $109.99 | +7,511% |
| May, 2026 | $80.71 | $63.35 | $98.34 | +6,014% |
| June, 2026 | $68.55 | $59.00 | $85.78 | +5,093% |
| July, 2026 | $67.43 | $59.00 | $85.62 | +5,008% |
| August, 2026 | $80.62 | $55.96 | $81.86 | +6,007% |
| September, 2026 | $81.49 | $69.91 | $86.39 | +6,073% |
| October, 2026 | $86.67 | $64.91 | $87.18 | +6,466% |
| November, 2026 | $64.57 | $58.01 | $88.64 | +4,791% |
| December, 2026 | $50.82 | $50.40 | $67.77 | +3,750% |
Fate Therapeutics Inc Stock (FATE) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Fate Therapeutics Inc (FATE) is $34.30, with a high forecast of $58.53 and a low forecast of $10.07. This indicates an +2,499% increase from the last price of $1.32.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $50.63 | $46.08 | $55.31 | +3,735% |
| February, 2027 | $47.73 | $44.12 | $56.88 | +3,516% |
| March, 2027 | $50.70 | $35.54 | $51.63 | +3,741% |
| April, 2027 | $35.36 | $32.41 | $58.53 | +2,578% |
| May, 2027 | $31.12 | $25.64 | $36.11 | +2,258% |
| June, 2027 | $24.86 | $22.46 | $34.61 | +1,783% |
| July, 2027 | $31.29 | $21.86 | $35.59 | +2,271% |
| August, 2027 | $27.29 | $26.62 | $35.71 | +1,968% |
| September, 2027 | $16.41 | $13.26 | $28.87 | +1,144% |
| October, 2027 | $14.01 | $10.07 | $18.04 | +961.57% |
| November, 2027 | $23.12 | $14.38 | $24.60 | +1,652% |
| December, 2027 | $27.10 | $20.14 | $30.41 | +1,953% |
Fate Therapeutics Inc Stock (FATE) Price Forecast for 2028
In 2028, Fate Therapeutics Inc (FATE) is projected to reach an average price of $15.04, with a high projection of $30.07 and a low estimate of $0.00614. This indicates an +1,039% rise from the last price of $1.32.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $20.14 | $18.44 | $30.07 | +1,426% |
| February, 2028 | $15.97 | $14.56 | $22.91 | +1,110% |
| March, 2028 | $14.65 | $12.16 | $17.54 | +1,010% |
| April, 2028 | $13.70 | $12.34 | $17.80 | +937.90% |
| May, 2028 | $5.0528 | $4.9328 | $15.41 | +282.79% |
| June, 2028 | $0.3491 | $0.3691 | $5.5518 | -73.55% |
| July, 2028 | $0.539 | $0.0951 | $1.399 | -59.17% |
| August, 2028 | $0.6284 | $0.108 | $1.4456 | -52.39% |
| September, 2028 | $0.4796 | $0.0696 | $0.5196 | -63.66% |
| October, 2028 | $0.4477 | $0.1142 | $1.4353 | -66.08% |
| November, 2028 | $0.1903 | $0.1887 | $0.5163 | -85.58% |
| December, 2028 | $0.1616 | $0.00614 | $0.9693 | -87.76% |
Fate Therapeutics Inc Stock (FATE) Price Forecast for 2029
The 2029 price forecast for Fate Therapeutics Inc Stock (FATE) is $4.2863 on average, with a high prediction of $8.42 and a low estimate of $0.1526. This represents an +224.72% increase from the previous price of $1.32.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $0.619 | $0.1526 | $0.449 | -53.10% |
| February, 2029 | $1.981 | $1.1045 | $1.781 | +50.07% |
| March, 2029 | $2.2729 | $2.0219 | $1.9029 | +72.19% |
| April, 2029 | $2.6348 | $2.3384 | $2.4248 | +99.61% |
| May, 2029 | $2.1022 | $2.2522 | $2.3913 | +59.26% |
| June, 2029 | $1.3741 | $1.7241 | $1.5227 | +4.10% |
| July, 2029 | $0.1461 | $0.4561 | $1.2796 | -88.93% |
| August, 2029 | $2.4465 | $0.237 | $2.9264 | +85.34% |
| September, 2029 | $3.3846 | $1.6476 | $4.1301 | +156.41% |
| October, 2029 | $3.2072 | $3.1291 | $5.3581 | +142.97% |
| November, 2029 | $1.5253 | $1.4303 | $4.2817 | +15.55% |
| December, 2029 | $9.185 | $0.5098 | $8.42 | +595.83% |
Fate Therapeutics Inc Stock (FATE) Price Forecast for 2030
Fate Therapeutics Inc Stock (FATE) is expected to reach an average price of $5.0473 in 2030, with a high forecast of $9.8141 and a low forecast of $0.2806. This signifies an +282.37% surge from the last price of $1.32.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $8.3998 | $7.2429 | $7.9123 | +536.35% |
| February, 2030 | $4.2987 | $5.8077 | $5.3067 | +225.66% |
| March, 2030 | $5.3125 | $3.8616 | $3.0716 | +302.46% |
| April, 2030 | $9.0464 | $8.1054 | $7.8364 | +585.33% |
| May, 2030 | $9.4812 | $8.0183 | $9.1912 | +618.27% |
| June, 2030 | $9.8151 | $10.91 | $9.8141 | +643.57% |
| July, 2030 | $10.05 | $9.747 | $9.4599 | +661.35% |
| August, 2030 | $3.7737 | $5.3337 | $8.9408 | +185.89% |
| September, 2030 | $2.0476 | $4.5947 | $3.9566 | +55.12% |
| October, 2030 | $5.3776 | $0.2806 | $5.4576 | +307.39% |
| November, 2030 | $3.3963 | $3.7057 | $9.0647 | +157.29% |
| December, 2030 | $0.3898 | $1.4592 | $4.8688 | -70.47% |
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):